Thursday, December 8, 2022
Mitochondrial Health

Targeting Metabesity 2020: Emerging Company Showcase – CohBar

Steve Engle, CEO (former)

A clinical stage biotechnology company focused on mitochondria-based therapeutics that originate from a novel group of naturally occurring peptide sequences within the mitochondrial genome. This emerging class of drugs for the treatment of chronic and age-related diseases includes the company’s lead compound, CB4211, which is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity.


Similar Posts

Leave a Reply

Your email address will not be published.